

**Amendments to the Claims**

1-8. (Canceled)

9. (Currently Amended) A pharmaceutical composition which comprises an effective amount of a Factor IXa compound and a pharmaceutically acceptable carrier, wherein the Factor IXa compound is selected from the group consisting of (i) an inactive Christmas factor, (ii) a carboxylated Christmas factor, (iii) a des- $\gamma$ -carboxyl Factor IX, (iv) Factor IX lacking a calcium-dependent membrane binding function, (v) Factor IX Bm Kiryu, (vi) Factor IXa having a post-translational modification selected from the group consisting of glycosylation,  $\beta$ -hydroxylation of aspartic acid, ~~carboxylation of glutamic acid~~ and propeptide cleavage, and (vii) an inactive mutein form of Factor IXa, wherein the inactive mutein form is selected from the group consisting of a Factor IXa having a Ser-185 to Ala substitution, and a Factor IXa with a different amino acid substituted for one or more of His-221, Asp-269 and Ser-365 ~~(viii) an anti-Factor IX antibody or fragment thereof, (ix) a small organic molecule, and (x) a peptidomimetic.~~

10-37. (Canceled)

38. (Previously Presented) The pharmaceutical composition of claim 9, wherein the inactive mutein form of Factor IXa is a Factor IXa having a Ser185 to Ala substitution.

Applicants: Eric Rose, et al.  
Serial No.: 10/646,493  
Filed: August 21, 2003  
Page 3

39-42. (Canceled)

43. (Previously Presented) The pharmaceutical composition of claim 9, wherein the inactive mutein form of Factor IXa is a Factor IXa with a different amino acid substituted for one or more of His-221, Asp-269 and Ser-365.

44. (Previously Presented) The pharmaceutical composition of claim 38, wherein the inactive mutein form of Factor IXa is a Factor IXa with a different amino acid substituted for one or more of His-41, Asp-89 and Ser-185 in the heavy chain of Factor IXa.